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Abstract
Lymphedema has always been a neglected global health care problem. A central requirement for the development of any
chronic disease is the clear use of public health definitions that can be used internationally to define populations. The term
‘‘lymphedema’’ has historically been defined as either primary, resulting from failure of lymphatic development, or
secondary, followingdamage to the lymphatics (e.g., cancer treatment, injury,orfilariasis).Attempts to integratecausesof
edema arising from damage to the venous system or the effects of gravity, immobility, and systemic disease have rarely
been integrated. More recently, the prominent role of the lymphatics in tissue fluid homeostasis in all forms of chronic
edema has been recognized. These advances led to the development of the term: ‘‘Chronic edema: a broad term used to
describe edema, which has been present for more than three months.’’ It can be considered an umbrella term that includes
not only conventional ‘‘lymphedema’’ but also chronic swelling, which may have a more complex cause. This definition
has been adapted in the international epidemiology study (LIMPRINT) that identified people throughout the health and
social care systems inparticipatingcountries.Clearerdefinitionswill allowforexaminationof this importantpublichealth
problem that is likely to escalate given the projections of an aging population with multiple comorbidities. It will be
possible to define both the hidden mortality and morbidity associated with complications, such as cellulitis and the impact
onhealth-relatedqualityof life.Thisevidence isurgently required to lobbyfor increased resourceandeffectivehealthcare
in an increasingly competitive health care arena in which more established conditions have greater priority and funding.
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The International Lymphedema Framework
The mission of the International Lymphedema Frame-work (ILF) is to improve the care of people with lym-
phedema and related disorders worldwide, which can only be
carried out when the problem is recognized as a neglected public
health problem that is largely ignored. The ILF, a charitable
organization with an international vision, has recognized since
its inception that there is a lack of global awareness of the size
and impact of people suffering with different forms of lym-
phedema and related disorders.1 This is an extraordinary and
unacceptable situation given the clinical and personal signifi-
cance for those affected by the condition and the decades of
research that have occurred in this field. Without this funda-
mental information, resources are unlikely to ever be allocated
for management, and further, the global challenges of lack of
reimbursement and low investment will maintain the status quo.
The ILF Response: LIMPRINT
The concept of designing and implementing an interna-
tional epidemiology study to address these issues emerged as
a key strategic aim for the ILF. There were many methodo-
logical challenges faced in creating systems that could be
used in countries with a diverse range of health care settings.
Such a vision was not for the weak hearted; it required a huge
commitment from many different stakeholders. At the very
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heart of this initiative was the belief in the power of part-
nership working; the ethos of the ILF and part of its motto—
belong together.
The development of LIMPRINT as an international epi-
demiology study required the engagement of multiple
stakeholders including: all national lymphedema frame-
works; clinicians; academics; patient organizations; the
medical device industry; and other organizations, for exam-
ple, charities. It has required a commitment from a diverse
range of countries and individual sites who have participated
to provide resources and to drive projects. All these initiatives
have received little or no direct funding but have sought local
research opportunities and benefited from effective academic
leadership. LIMPRINT has formed the largest international
epidemiology project on lymphedema to date.
Who Is Affected by Lymphedema?
The Myth of a Rare Disorder
Lymphedema has always been a neglected area of health
care. This has largely been because it has been misunderstood
and thought to be a rare condition. In many parts of the world
such as India and Africa, it is recognized as a neglected
tropical disorder caused by filariasis, a parasitic condition
spread by mosquitoes.2 In western populations, the causes are
very different3–6 Nevertheless, there is a huge hidden burden
of morbidity that spans all afflicted populations irrespective
of where they are found across the world. Additionally, there
is a failure to recognize the hidden mortality associated with
complications such as cellulitis and a nihilistic view that no
effective treatment exists. These beliefs have led to a lack of
investment in service provision and research into the causes,
treatment, and management. All these assumptions are funda-
mentally incorrect and are what the ILF and the other organi-
zations dedicated to improving care are trying to challenge.
Children with Lymphedema: A Truly Rare Condition
Lymphedema occurring in children and adolescents is
correctly defined as a rare condition.7 Despite this, we have
little international epidemiology on how many children are
afflicted as most countries do not collect this information.
This compounds the suffering for children and their families
who require accurate diagnosis, genetic screening, and ap-
propriate treatment within their own countries. For some,
they are forced to seek help from international experts and
travel abroad for treatment. The ILF recognizes the impor-
tance of this group and is seeking to develop an international
response to address this. The determination of the genetic
causes of lymphedema is a rapidly developing field of re-
search with the identification of new causes for a proportion
of those affected. This offers the hope of targeted interven-
tions and a possible cure. Research is of critical importance
since some secondary lymphedema may have an underlying
genetic predisposition, impacting on the risk of its develop-




Adults with chronic edema are found in many parts of the
health and social care systems.8,9 Despite this, professional
knowledge is often poor leading to a lack of diagnosis and
treatment. Both patients and professionals frequently ignore
the early presentation of swelling until complications such as
irreversible tissue changes, chronic wounds, cellulitis, or loss
of function occur.
In many developed countries, the focus of lymphedema
management and research has been on that resulting from the
treatment of cancer. It is only in recent years that other causes
have been given greater attention, and it is now recognized
that cancer-related lymphedema constitutes only a relative
minority of the total cases.
Lymphedema or Chronic Edema:
The Importance of Definition
A central requirement for the development of any chronic
disease is the clear use of public health definitions that can be
used internationally to define the different patient popula-
tions. Only then can the risk factor profiles be identified, and
targeted treatments developed. This has been a major prob-
lem for the field of lymphedema and its related disorders. It
has led to confusion for the general public and professionals
and has potentially affected its recognition as a health care
problem.
Confusion over who can ‘‘claim’’ to be suffering from
lymphedema is such a significant issue that it underpins the
reimbursement and provision of care in many countries. In
some, payment is only provided for those with lymphedema
linked to cancer or those with a primary form confirmed by
clinical investigation. In countries where lymphedema is a
neglected tropical disease, there is a tendency for all those
living in these areas to be classified as suffering from
filariasis-related lymphedema, even though many will have
other forms of lymphedema.
The changing perspectives on definition
The term ‘‘lymphedema’’ has historically been defined as
edema, which develops as a result of failure of lymphatic
drainage either through problems in lymphatic development
(primary lymphedema) or through damage to the lymphatics
(secondary lymphedema; e.g., following cancer treatment).
Edema arising from venous disease is not always considered
to be a secondary type of lymphedema, although there is
evidence of lymphatic failure in chronic venous disease with
edema where the term ‘‘phlebolymphedema’’ is often used.5
Complex patient profiles
In many clinical situations such as in the elderly with
multiple comorbidities, many factors may contribute to the
etiology of chronic swelling, for example, immobility, heart
failure, chronic venous hypertension, and drugs. A few health
care professionals would consider this swelling to be lym-
phedema. However, this type of chronic swelling does in-
volve failure of lymphatic drainage with significant resulting
morbidity.
Furthermore, in some types of lymphedema, which have
previously been considered to be purely due to problems with
lymphatic drainage, for example, breast cancer-related lym-
phedema, and some types of primary lymphedema, for example,
lymphedema–distichiasis (in which there are malfunctioning
lymphatic and venous valves), there is growing evidence of a
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more complex cause including a venous component and ge-
netic predisposition to its development.10,11
The recognition of the complex patients presenting to a
national United Kingdom specialist service led to the de-
velopment of the term ‘‘chronic edema.’’ This was used in the
prevalence study carried out in 2003.8 The definition used in
this study is defined below:
‘‘Chronic oedema is a broad term used to describe
oedema which has been present for more than three
months and involves one or more of the following ar-
eas: limbs, hands/feet, upper body (breast/chest wall,
shoulder, back), lower body (buttocks, abdomen),
genital (scrotum, penis, vulva), head, neck or face.’’
Thus, ‘‘chronic edema’’ can be considered to be an um-
brella term that includes not only conventional ‘‘lymphede-
ma’’ but also chronic swelling, which may have a more
complex cause.
Chronic edema therefore includes:
 Lymphedema (primary and secondary)
 Venous edema
 Chronic swelling due to immobility
 Edema related to advanced cancer
 Chronic swelling associated with lipedema
 Chronic swelling related to obesity
 Chronic swelling associated with rare vascular mal-
formations such as Klippel–Trenaunay syndrome.
New understanding of the physiology
In recent years, our understanding of the physiology of
tissue fluid formation and drainage has developed further and
supports the concept that the lymphatics are involved in all
forms of chronic edema.12
The Starling model proposed that fluid flow out of capil-
laries into the tissues was governed by net outcome of op-
posing pressures across the capillary wall. The pressures
concerned are the hydrostatic pressure and the colloid osmotic
(oncotic) pressure gradients. The flow rate is also governed by
the permeability of the capillary wall. The hydrostatic pressure
gradient is the physical pressure inside the capillary compared
with that outside. The colloid osmotic pressure arises from the
attraction of water by proteins and therefore the pressure
gradient is due to the difference in protein concentration be-
tween the plasma and the tissue fluid.
In the original model, measurements of these pressures
available at that time suggested that there was an outflow of
fluid from the arteriolar end of the capillary and reabsorp-
tion of fluid into the venous end of the capillary, with only
*10% of the tissue fluid being drained through the lym-
phatic system.
A more recent, more sophisticated understanding of the
ultrastructure of the capillaries and more accurate measure-
ments of the various pressures involved has led to a revision
of these ideas. It is now thought that in the steady state, in
most capillary beds, there is net outflow of fluid all along the
capillary with no reabsorption at the venous end. This means
that all the excess capillary filtrate and macromolecules in the
interstitial space are taken up by the lymphatics. This gives
the lymphatics a much greater role in tissue fluid homeostasis
than previously understood.12
Edema arises when capillary filtration exceeds lymphatic
drainage. If lymphatic drainage is reduced and capillary fil-
tration is normal, edema develops (known as lymphedema if
persistent/chronic). If capillary filtration is increased, then
the lymphatics drain more fluid to prevent edema formation.
In this situation, edema only develops when capillary filtra-
tion exceeds the maximum capacity of the lymphatics to
drain fluid. Thus, it can be argued that all edema has a lym-
phatic component, whether it is due primarily to a lymphatic
problem or to other factors, which cause an increase in cap-
illary filtration.
It could therefore be argued that all chronic edema should
be considered to be lymphedema. In this case, all the more
complex types of chronic edema (e.g., that due to venous
disease and advanced cancer) would be considered to be
types of secondary lymphedema.
From a clinical viewpoint, whichever term is used, chronic
edema or a broader understanding of the term ‘‘lymphede-
ma,’’ it is still important to consider the underlying factors,
which may be causing the swelling as this may influence
treatment. Therefore, the term ‘‘chronic edema’’ is a useful
umbrella term and should be used in public health studies but
in itself it does not define the underlying cause(s) and is not a
diagnosis.
When considering studies of prevalence, it is again impor-
tant that the broader meaning of lymphedema or the term
‘‘chronic edema’’ is used synonymously to encompass the
more complex causes of chronic swelling. In publications of
prevalence studies to date, some use the term ‘‘chronic edema’’
and others the term ‘‘chronic edema/lymphedema.’’8,13–15
Methodology for determining prevalence
How common a chronic condition is can be determined by
measuring the prevalence of the condition in the population at
one point in time (point prevalence). Crude prevalence is a
measure of all people with the condition at a single time
point. This does not take into account any variation that may
occur in the population such as age or gender. Measuring
differences in prevalence in different age groups allows
standardization of the prevalence calculation. This in turn
enables comparisons to be made between the prevalence in
different populations taking account of the influence of dif-
ferent age distributions. Comparison between prevalence
data from different settings is also facilitated by defining the
population in which the prevalence was measured and having
a consistent definition of the condition concerned.
To measure how common lymphedema is in a given
country, the number of people with lymphedema in the
population of that country would need to be determined at a
given time point. Population-based studies are difficult to
carry out from a practical point of view and are also expen-
sive. Alternative methods can, however, yield useful infor-
mation. One such method is to measure the number of people
with lymphedema known to health care professionals in a
given population. This assumes that all people with lym-
phedema are known to local health services, which, as al-
ready discussed, is unlikely given the lack of professional
knowledge and public awareness.
Furthermore, in an ideal situation, there would be some
form of routine data collection or register for those with
lymphedema, which could be interrogated to determine the
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prevalence in each country using agreed definitions and
standardized coding. Unfortunately, while in some countries
this occurs, (particularly in those with insurance-based health
care systems), this is not standardized internationally.
Therefore, case ascertainment methodology, which in-
cludes carrying out a survey of health care professionals in a
given population, asking them for details of people known
to them with chronic edema, in addition to prospective
clinical assessment of patients within the health care sys-
tems, is an appropriate compromise that yields important
results. It is this which forms the core of the LIMPRINT
methodology.
This approach can also be used to determine the prevalence
in smaller populations such as those with another chronic
clinical condition where chronic swelling is known to occur,
for example, multiple sclerosis.4 This still requires a database
of those with the other chronic conditions, which is kept up-
to-date to define the population (denominator) accurately.
Cross-sectional-based prevalence studies can be under-
taken in defined health care settings such as hospitals or care
homes where the population is fixed over a short time period.
In these settings, a visiting team of researchers can determine
the number of people and clinically assess them, thereby
deriving an accurate estimation of the prevalence in that
setting at that particular time point.
The importance of incidence data
In some situations, the measurement of the incidence of
lymphedema/the risk of developing lymphedema, for exam-
ple, after breast cancer treatment, can also be valuable. In-
cidence measures the number of new cases over a given time
period. In the case of breast cancer-related lymphedema, the
condition most commonly develops within 2 years of the
initial cancer treatment, but it is known that some women do
not develop lymphedema until many years later even in the
absence of recurrent disease. This means that in studies of
incidence where the lifelong risk of developing breast cancer-
related lymphedema is being determined, the time period of
follow-up must be sufficiently long, for example more than 3
years to give the most accurate estimate.
Whether measuring prevalence or incidence, it is impor-
tant that the diagnosis of ‘‘lymphedema’’ is defined and used
consistently. This has been clearly illustrated in the case of
lymphedema following breast cancer treatment where a
number of different definitions of lymphedema judged by
limb volume changes following surgery compared with
preoperative measurements have been used. Using defini-
tions of volume changes of 200 mL, 5% or 10% give very
different estimates of incidence.3
Epidemiological studies of chronic edema
in the United Kingdom
The first study to use the definition of chronic edema was
reported in 2003.8 The aims of the study were to determine the
magnitude of the problem of chronic edema in health services
within an urban area of London, United Kingdom, and to
assess the likely impact of edema on use of health resources,
employment, and patient’s quality of life. The study used a
questionnaire-based survey given to health professionals
followed by an interview and clinical assessment in a random
sample. Health professionals from dedicated lymphedema
services, specific outpatient clinics, hospital wards, and
community services (general practitioner clinics and district
nurses) were contacted to provide information on patients
from within the geographical area who were known to suffer
with chronic edema of greater than 3 months duration.
Within the catchment area with a population of 619,000
people, 823 patients had chronic edema (crude prevalence
1.33/1000). Prevalence increased with age (5.4/1000 in those
aged >65 years) and was higher in women (2.15 vs. 0.47/
1000). Only 529 (64%) were receiving treatment, despite 2
specialist lymphedema clinics within the catchment area. Of
228 patients interviewed, 78% had edema lasting >1 year.
Over the previous year, 64 of 218 (29%) had had an acute
infection in the affected area, with 17 of 64 (27%) being
admitted for intravenous antibiotics. The mean length of stay
for this condition was 12 days, with an estimated mean cost of
£2300 (2003 data). Edema caused time off work in >80% and
affected employment status in 9%. Quality of life was below
normal, with 50% experiencing pain or discomfort from their
edema.
Using an extrapolation of these figures, it was estimated
that at least 100,000 patients were suffering in the United
Kingdom alone. However, it is acknowledged that this will be
an underestimate of the true prevalence within the general
population for the reasons described above.
This methodology was repeated over 10 years later in an
urban population of the East Midlands in the United King-
dom.9 This cross-sectional study was carried out in Derby
City (United Kingdom), which has a population of
*247,100. Data were obtained from 10 sources, namely the
inpatients of 1 acute and 1 community hospital, 1 specialist,
and 3 nonspecialist outpatient clinics (dermatology, plastic
surgery, and diabetic foot clinic), all community nursing
services, general practices (n = 41), and nursing/residential
homes (n = 26) in the catchment area.
Within the study population of Derby City residents, 971
patients were identified with chronic edema (estimated crude
prevalence 3.93/1000, 95% [confidence interval 3.69–4.19]).
The prevalence was highest among those aged 85 years or
older (28.75/1000) and was higher among women (5.37/
1000) than men (2.48/1000). The prevalence among hospital
inpatients was 28.5%. Only five (3%) patients in the com-
munity population had edema related to cancer or cancer
treatment. Patients with cancer-related lymphedema were
usually treated by hospital-based services in Derby. Of the
304 patients identified with edema from the Derby hospitals
or community health services, 121 (40%) had a concurrent
leg ulcer.
Study comparison
Data obtained from this study differ greatly from those
obtained previously, even though the same methods were
adopted. In the 2003 London study, the crude prevalence was
approximately one third of that reported in 2016. When
standardized to the population of England, this difference
was reduced slightly to three times that observed in London,
with adjusted rates for Derby City and South West London
(4.15/1000 and 1.55/1000, respectively). It is unlikely that
this difference can be attributed to methodological dis-
crepancies or variations in the populations studied, as both
samples were derived from an urban community. It is
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possible that differences in characteristics of the population
other than age and gender such as obesity may be partially
responsible for the higher prevalence. Other findings were
comparable to the earlier London study, for example, the
prevalence was much higher among women than men. It was
also more prevalent among the obese and was highest among
people older than 85 years.
Analysis of the data by site of swelling (n = 889) indicates
that the proportion of patients with lower limb edema was
much higher in Derby City than in the London study. This
may have occurred because of a greater awareness of chronic
edema in Derby, which may have led to a larger number of
referrals of patients with lower limb edema to the Derby
service compared with South West London. If this is the case,
some of the difference in overall estimated prevalence could
be attributed to greater identification of lower limb edema
rather than a truly higher overall prevalence. This is unlikely,
however, as both specialist services in Derby and South West
London are well-known centers of excellence that have been
established for many years.
Hospital inpatient services
Nearly one third of the hospital inpatient population had
chronic edema. This may be because a number of conditions
are associated with its occurrence, and it can be caused by a
variety of underlying pathophysiological mechanisms. This
finding also dispels the commonly held belief that chronic
edema is confined to those seen by community-based health
services. While it is well recognized that many ‘‘community
patients’’ have venous leg ulceration, this study highlights
that many of these also have concurrent chronic edema, an
association that has received scant attention previously.
Obesity and chronic edema
The East Midlands data support the hypothesis that obesity
is a common feature of patients with chronic edema seen by
specialist services in western populations. A number of
mechanisms have been postulated to explain this relation-
ship. These include impaired lymphatic flow, chronic in-
flammation, elevated production of interstitial fluid, and
reduced mobility in obesity. Obesity is also implicated in the
development of chronic edema among people with cancer
and those with other long-term conditions, particularly those
who are wheelchair users.16,17
Study limitations
One limitation of this study is that comprehensive data
could not be obtained from General Practices as diagnostic
codes have not been created in the United Kingdom health
service. Poor recognition and limited knowledge may have
limited the number of patients identified, particularly in
nursing/residential home settings where the proportion of
qualified staff is low. Of greater importance is the lack of
awareness among the general population, as this limits the
number of people who present to health services. It is very
difficult to estimate the true percentage of the population as
symptoms can develop at a relatively late stage. A major
strength of this study is that patients were surveyed in all
public health service settings available to Derby City resi-
dents and all nursing/residential homes.
Conclusions
A systematic review has indicated that there is a dearth of
population-based epidemiological studies to define the
prevalence of chronic edema and little robust evidence of the
cost and clinical effectiveness of different models of care.18
The studies undertaken in the United Kingdom created
the impetus behind the concept of LIMPRINT with the
possibility to assess the number of people with chronic
edema in different health care services using an interna-
tionally agreed protocol of assessment and validated data
collection methods. This will be discussed further in the
following articles.
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